Dallas, Texas 07/01/2015 (Financialstrend) – Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has recently announced the publication of a review article that describes the potential of using HSP90 as a complementary strategy in certain stages of cancer. The study was published in the Cancer Immunology Research journal in the current month. The journal is published by American Association for Cancer Research. It features original articles in the field of oncology research from time to time. This recent article seems to have grabbed the attention of the company as the company is trying to test HSP90 inhibitor.
Synta and Heat-Shock Protein 90
The company has currently undertaken a study for ganetespib, a HSP 90 inhibitor. The company is involved in different randomized studies for the same inhibitor. It has also participated in GALAXY -2 trials. GALAXY -2 is a well-known global randomized study that involves ganetspib and docetaxel. The study is multi-center and intended for treatment of advanced non-small cell lung adenocarcinoma.
The biopharmaceutical company has been trying to commercialize the latest advances in oncology medicine and HSP 90 seems to be the current choice for company’s research team.
The Report Highlights
The report discusses Heat-Shock Protein 90 as it applies to immune checkpoint blockade in the therapy for cancer. It features preclinical findings. These findings suggest a positive response from the immune system for HSP 90. Ganetespib was used in anti PD-L1 anti body treatment. The article also mentioned some key immune checkpoints and HSP 90. It is suggested that the approach may be beneficial as a complementary strategy.
The immune checkpoint inhibitors need to be studied further before any definitive comment can be made in this matter but the overall article favors the study of HSP 90 inhibitors.
Chen Schor, CEO of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) seems to be impressed by the article as he mentioned that his company will continue to study and explore the benefits of potential combinations of ganetespib in clinical trials. The company will likely publish the results of their findings soon.